This health education program aims to help patients living with COPD experience better health outcomes and improved quality of life for the duration of their lives.

General Manager at Sanofi UK and Ireland, Rippon Ubhi, and Jim Shannon MP discuss the burden of chronic obstructive pulmonary disease (COPD) on patients and the NHS, and the healthcare ...

The deal is the latest in a series of Sanofi investments in its immunology portfolio. According to Sanfoi, DR-0201 can ...

Proactive, patient-centred care is essential to navigate the challenges of the winter season. Collaboration at the heart of improving COPD care At Sanofi, we are committed to standing with the ...

Dupilumab vs placebo was linked to improved health-related quality of life and respiratory symptoms in patients with COPD and T2 inflammation.

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

COPD is an inflammatory lung disease ... NAH received honoraria for serving as an advisor/consultant for GSK, Sanofi, Genentech, Verona Pharma, Astra Zeneca, and Boehringer Ingelheim, and research ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...